dry eye disease diabetes
Conditions
Interventions
Use of platelet-rich drops, done in hemocenter by autologous donation, and used in 12 diabetic patients with moderate to severe dry eye unresponsive to conventional therapy, administered one drop eve
Biological/vaccine
Sponsors
Hemocentro de Alagoas-HEMOAL
Universidade Federal de Alagoas
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Diagnose of diabetes following ADA (American Diabetes Association)criteria;moderate or severe dry eye patients with unresponsiveness or a weak response to conventional treatment; having at least a frequent or constant symptom and either a Schirmer test at less than 15mm or a BUT(Break Up Time test) less than 10 seconds.
Exclusion criteria
Exclusion criteria: Individuals under 18; mentally disabled; pregnant women; indigenous people and those who are wards of the state. Patients that had keratopathies; use of glaucoma eyedrops; previous rheumatic disease diagnosis. Patients that had contraindicated conditions to be submitted to autologous donation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of the symptoms of dry eye, graduated byspecific questionnaire, with decreased frequency of complaints, measured in standardized scale 1-4; and through objective tests Schirmer and tear film break-up time, with gradation 1-4 by the criteria of the Dry Eye Workshop-Delphi panel. Considered improved when when grading after 1 month of treatment is 1 or 2 for both cases. | — |
Countries
Brazil
Contacts
Public ContactEurica;Marina Ribeiro;Ribeiro
Universidade Federal de Alagoas;Universidade Federal de Alagoas
Outcome results
None listed